全文获取类型
收费全文 | 3507029篇 |
免费 | 286492篇 |
国内免费 | 15965篇 |
专业分类
耳鼻咽喉 | 47360篇 |
儿科学 | 111840篇 |
妇产科学 | 91320篇 |
基础医学 | 557581篇 |
口腔科学 | 94111篇 |
临床医学 | 323357篇 |
内科学 | 616478篇 |
皮肤病学 | 90905篇 |
神经病学 | 301529篇 |
特种医学 | 135283篇 |
外国民族医学 | 393篇 |
外科学 | 529487篇 |
综合类 | 106719篇 |
现状与发展 | 23篇 |
一般理论 | 2296篇 |
预防医学 | 303633篇 |
眼科学 | 79419篇 |
药学 | 240577篇 |
27篇 | |
中国医学 | 10473篇 |
肿瘤学 | 166675篇 |
出版年
2021年 | 55479篇 |
2020年 | 35360篇 |
2019年 | 58394篇 |
2018年 | 72116篇 |
2017年 | 54999篇 |
2016年 | 60561篇 |
2015年 | 74580篇 |
2014年 | 108889篇 |
2013年 | 174470篇 |
2012年 | 99491篇 |
2011年 | 100661篇 |
2010年 | 119078篇 |
2009年 | 122495篇 |
2008年 | 86382篇 |
2007年 | 89701篇 |
2006年 | 99998篇 |
2005年 | 95117篇 |
2004年 | 96286篇 |
2003年 | 86596篇 |
2002年 | 76233篇 |
2001年 | 107524篇 |
2000年 | 100878篇 |
1999年 | 99575篇 |
1998年 | 65724篇 |
1997年 | 63549篇 |
1996年 | 61251篇 |
1995年 | 56852篇 |
1994年 | 51017篇 |
1993年 | 47601篇 |
1992年 | 70840篇 |
1991年 | 67962篇 |
1990年 | 64495篇 |
1989年 | 62891篇 |
1988年 | 58454篇 |
1987年 | 57101篇 |
1986年 | 54489篇 |
1985年 | 54358篇 |
1984年 | 49322篇 |
1983年 | 44936篇 |
1982年 | 42055篇 |
1981年 | 39636篇 |
1980年 | 37283篇 |
1979年 | 40825篇 |
1978年 | 35947篇 |
1977年 | 32501篇 |
1976年 | 30328篇 |
1975年 | 28579篇 |
1974年 | 30055篇 |
1973年 | 28944篇 |
1972年 | 27112篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
51.
I. R. Reid 《Journal of internal medicine》2015,277(6):690-706
There is an increasing number of effective therapies for fracture prevention in adults at risk of osteoporosis. However, shortcomings in the evidence underpinning our management of osteoporosis still exist. Evidence of antifracture efficacy in the groups of patients who most commonly use calcium and vitamin D supplements is lacking, the safety of calcium supplements is in doubt, and the safety and efficacy of high doses of vitamin D give cause for concern. Alendronate, risedronate, zoledronate and denosumab have been shown to prevent spine, nonspine and hip fractures; in addition, teriparatide and strontium ranelate prevent both spine and nonspine fractures, and raloxifene and ibandronate prevent spine fractures. However, most trials provide little information regarding long‐term efficacy or safety. A particular concern at present is the possibility that oral bisphosphonates might cause atypical femoral fractures. Observational data suggest that the incidence of this type of fracture increases steeply with duration of bisphosphonate use, resulting in concern that the benefit–risk balance may become negative in the long term, particularly in patients in whom the osteoporotic fracture risk is not high. Therefore, reappraisal of ongoing use of bisphosphonates after about 5 years is endorsed by expert consensus, and ‘drug holidays’ should be considered at this time. Further studies are needed to guide clinical practice in this area. 相似文献
52.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies 下载免费PDF全文
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献
53.
54.
55.
56.
57.
58.
59.
Methicillin‐resistant Staphylococcus aureus eradication in young infants should include the diaper area and treat housing contacts 下载免费PDF全文
60.